Item 5. OTHER INFORMATION

Securities Trading Plans of Directors and Executive Officers

During our fiscal quarter ended July 31, 2023, the following directors and officers, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:

On May 26, 2023, Dr. Andrew Anagnost, our CEO, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 112,061 shares of our common stock, net of shares withheld for taxes. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until April 26, 2024, or earlier if all transactions under the trading arrangement are completed.

On May 26, 2023, Deborah L. Clifford, our CFO, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 41,149 shares of our common stock, net of shares withheld for taxes. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until April 12, 2024, or earlier if all transactions under the trading arrangement are completed.

On June 30, 2023, Lorrie Norrington, one of our Directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 2,148 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until December 29, 2023, or earlier if all transactions under the trading arrangement are completed.

No other officers or directors, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, during the fiscal quarter ended July 31, 2023.